Carsten Dehning
Directeur Financier/CFO chez Bourn Hall LLC
Profil
Carsten Dehning is currently the Chief Financial Officer at Bourn Hall LLC.
Previously, he served as the Chairman & Chief Executive Officer at Aspireo Pharmaceuticals Ltd.
and as the Chief Financial Officer & Director at DeveloGen AG.
He also worked as a Principal at Preussag AG.
Postes actifs de Carsten Dehning
| Sociétés | Poste | Début |
|---|---|---|
Bourn Hall LLC
 Bourn Hall LLC Hospital/Nursing ManagementHealth Services Bourn Hall LLC offers fertility treatment programs. It offers assisted reproductive technology, genetic testing and gender balancing, men's health, gynecology surgeries, fertility preservation, cosmetic gynecology, female fertility treatments, male fertility treatments, and Platelet Rich Plasma. The company was founded in 2012 and is headquartered in Dubai, the United Arab Emirates. | Directeur Financier/CFO | - |
Anciens postes connus de Carsten Dehning
| Sociétés | Poste | Fin |
|---|---|---|
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Directeur Financier/CFO | 25/01/2012 |
Aspireo Pharmaceuticals Ltd.
 Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Directeur Général | - |
| Preussag AG | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
| Preussag AG | Consumer Services |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |
Bourn Hall LLC
Bourn Hall LLC Hospital/Nursing ManagementHealth Services Bourn Hall LLC offers fertility treatment programs. It offers assisted reproductive technology, genetic testing and gender balancing, men's health, gynecology surgeries, fertility preservation, cosmetic gynecology, female fertility treatments, male fertility treatments, and Platelet Rich Plasma. The company was founded in 2012 and is headquartered in Dubai, the United Arab Emirates. | Health Services |